Valuation: ACLS THER

Market Cap 932M 798M 744M 683M 1.28B 89.16B 1.31B 8.83B 3.44B 44.68B 3.5B 3.42B 148B P/E 2026 *
-9.69x
P/E 2027 * -7.82x
Enterprise Value 779M 667M 622M 571M 1.07B 74.51B 1.09B 7.38B 2.88B 37.34B 2.92B 2.86B 124B EV / Sales 2026 *
124x
EV / Sales 2027 * 152x
Free-Float
97.82%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 16/01/2024
President 67 17/11/2024
Director of Finance/CFO 39 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2022
Director/Board Member 50 31/08/2014
Director/Board Member 59 31/08/2016
Change 5-day change 1-year change 3-year change Capi.($)
+2.38%+5.57%+86.02%+115.89% 72.21B
+0.87%+17.34%+57.17%+97.28% 63.98B
-4.27%-0.99%-3.38%+475.61% 28.53B
+3.63%+8.62%+66.69%+23.95% 25.07B
-1.97%+20.38%-0.37%+0.48% 28.42B
-0.51%+5.11%+41.27%-12.79% 20.04B
-1.79%-4.51%+241.26%+414.48% 18.19B
+1.81%+0.85%+16.89%+546.06% 15.96B
-1.29%+6.09%+41.81%+154.45% 13.48B
Average -0.13%+5.63%+60.82%+201.71% 31.76B
Weighted average by Cap. +0.38%+7.48%+61.16%+163.91%

Financials

2026 *2027 *
Net sales 6.29M 5.38M 5.02M 4.61M 8.66M 602M 8.83M 59.58M 23.23M 301M 23.61M 23.09M 998M 5.18M 4.44M 4.14M 3.8M 7.14M 496M 7.28M 49.11M 19.14M 248M 19.46M 19.03M 823M
Net income -91.02M -77.93M -72.71M -66.72M -125M -8.71B -128M -863M -336M -4.36B -342M -334M -14.45B -114M -97.8M -91.25M -83.73M -157M -10.93B -160M -1.08B -422M -5.48B -429M -420M -18.13B
Net Debt -153M -131M -122M -112M -211M -14.65B -215M -1.45B -566M -7.34B -575M -562M -24.31B -147M -125M -117M -107M -202M -14.02B -206M -1.39B -541M -7.03B -550M -538M -23.27B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-